Srini Ramanathan

1.0k total citations
34 papers, 833 citations indexed

About

Srini Ramanathan is a scholar working on Genetics, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Srini Ramanathan has authored 34 papers receiving a total of 833 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 8 papers in Infectious Diseases and 7 papers in Molecular Biology. Recurrent topics in Srini Ramanathan's work include Chronic Lymphocytic Leukemia Research (14 papers), HIV/AIDS drug development and treatment (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Srini Ramanathan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), HIV/AIDS drug development and treatment (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Srini Ramanathan collaborates with scholars based in United States and United Kingdom. Srini Ramanathan's co-authors include Edwin DeJesus, Kitty Yale, Huafeng Zhou, Marshall W. Fordyce, Martin S. Rhee, Lijie Zhong, Daniel Berger, Martin Markowitz, Feng Jin and Peter Ruane and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Srini Ramanathan

33 papers receiving 814 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Srini Ramanathan United States 11 417 338 210 133 113 34 833
Rachid Agher France 18 519 1.2× 238 0.7× 433 2.1× 49 0.4× 53 0.5× 33 1.1k
Sanit Makonkawkeyoon Thailand 9 324 0.8× 250 0.7× 88 0.4× 84 0.6× 28 0.2× 20 862
S Weller United States 15 450 1.1× 547 1.6× 215 1.0× 19 0.1× 92 0.8× 66 1.1k
Jean Marie Arduino United States 18 614 1.5× 490 1.4× 433 2.1× 50 0.4× 257 2.3× 37 1.8k
Giovanna Melica France 15 222 0.5× 190 0.6× 88 0.4× 219 1.6× 17 0.2× 51 682
F. Schöni-Affolter Switzerland 12 242 0.6× 262 0.8× 93 0.4× 13 0.1× 61 0.5× 18 889
Tomoko Uehira Japan 12 212 0.5× 131 0.4× 103 0.5× 25 0.2× 62 0.5× 54 475
Jan‐Christian Wasmuth Germany 16 185 0.4× 274 0.8× 139 0.7× 36 0.3× 115 1.0× 46 712
Bobbie Graham United States 13 440 1.1× 206 0.6× 314 1.5× 29 0.2× 16 0.1× 24 1.0k
Dariela Micheloud Spain 18 247 0.6× 335 1.0× 172 0.8× 21 0.2× 26 0.2× 48 780

Countries citing papers authored by Srini Ramanathan

Since Specialization
Citations

This map shows the geographic impact of Srini Ramanathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Srini Ramanathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Srini Ramanathan more than expected).

Fields of papers citing papers by Srini Ramanathan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Srini Ramanathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Srini Ramanathan. The network helps show where Srini Ramanathan may publish in the future.

Co-authorship network of co-authors of Srini Ramanathan

This figure shows the co-authorship network connecting the top 25 collaborators of Srini Ramanathan. A scholar is included among the top collaborators of Srini Ramanathan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Srini Ramanathan. Srini Ramanathan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yan, Xin, Fengyan Xu, Yuying Gao, et al.. (2021). Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease. Clinical Pharmacokinetics. 60(8). 1029–1040. 18 indexed citations
3.
Ramanathan, Srini, et al.. (2016). Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers. Clinical Drug Investigation. 37(2). 195–205. 19 indexed citations
4.
Ramanathan, Srini, Joseph M. Custodio, Xuelian Wei, et al.. (2016). Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects. JAIDS Journal of Acquired Immune Deficiency Syndromes. 72(3). 281–288. 10 indexed citations
5.
Custodio, Joseph M., Toufigh Gordi, Lijie Zhong, Kah Hiing John Ling, & Srini Ramanathan. (2015). Population Pharmacokinetics of Boosted‐Elvitegravir in HIV‐Infected Patients. The Journal of Clinical Pharmacology. 56(6). 723–732. 6 indexed citations
6.
Jin, Feng, et al.. (2015). The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment. Cancer Chemotherapy and Pharmacology. 76(6). 1133–1141. 12 indexed citations
7.
Jin, Feng, et al.. (2015). Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies. Cancer Chemotherapy and Pharmacology. 77(1). 89–98. 10 indexed citations
8.
Jin, Feng, et al.. (2015). Exposure-response analysis from a Phase 2 study of the Syk inhibitor entospletinib in patients with relapsed or refractory hematologic malignancies.. Journal of Clinical Oncology. 33(15_suppl). e13584–e13584. 1 indexed citations
9.
10.
DeVincenzo, John P., Richard J. Whitley, Richard L. Mackman, et al.. (2014). Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study. New England Journal of Medicine. 371(8). 711–722. 256 indexed citations
11.
Jin, Feng, et al.. (2014). Drug interaction profile of idelalisib and its major metabolite, GS-563117.. Journal of Clinical Oncology. 32(15_suppl). 2593–2593. 5 indexed citations
12.
Jin, Feng, et al.. (2014). Abstract 4633: Pharmacokinetics, metabolism and excretion of idelalisib. Cancer Research. 74(19_Supplement). 4633–4633. 3 indexed citations
13.
Jin, Feng, et al.. (2014). Abstract CT217: Pharmacokinetics and safety of idelalisib, a novel PI3Kδ inhibitor, in Japanese and Caucasian subjects. Cancer Research. 74(19_Supplement). CT217–CT217. 3 indexed citations
14.
Ruane, Peter, Edwin DeJesus, Daniel Berger, et al.. (2013). Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(4). 449–455. 247 indexed citations
15.
Mills, Anthony, Calvin Cohen, Edwin DeJesus, et al.. (2013). Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate–Based Single-Tablet Regimens. HIV Clinical Trials. 14(5). 216–223. 61 indexed citations
16.
Jin, Feng, et al.. (2013). The Pharmacokinetics and Safety Of Idelalisib In Subjects With Severe Renal Impairment. Blood. 122(21). 5572–5572. 6 indexed citations
17.
Jin, Feng, et al.. (2013). The Pharmacokinetics and Safety Of Idelalisib In Subjects With Moderate Or Severe Hepatic Impairment. Blood. 122(21). 5571–5571. 5 indexed citations
18.
Jin, Feng, et al.. (2013). Evaluation Of The Effect Of Idelalisib On The QT/QTc Interval In Healthy Subjects. Blood. 122(21). 5573–5573. 7 indexed citations
19.
Jin, Feng, et al.. (2013). Pharmacokinetics, Metabolism and Excretion Of Idelalisib. Blood. 122(21). 5570–5570. 23 indexed citations
20.
Terrault, Norah A., Tram T. Tran, Eugene R. Schiff, et al.. (2009). Pharmacokinetics of tacrolimus co‐administered with adefovir dipivoxil to liver transplant recipients. Liver International. 29(8). 1178–1183. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rachid Agher Breakdown of academic impact, for papers by Sanit Makonkawkeyoon Breakdown of academic impact, for papers by S Weller Breakdown of academic impact, for papers by Jean Marie Arduino Breakdown of academic impact, for papers by Giovanna Melica Breakdown of academic impact, for papers by F. Schöni-Affolter Breakdown of academic impact, for papers by Tomoko Uehira Breakdown of academic impact, for papers by Jan‐Christian Wasmuth Breakdown of academic impact, for papers by Bobbie Graham Breakdown of academic impact, for papers by Dariela Micheloud
Rankless by CCL
2026